Relapse Rate 18.6 Percent for Ulcerative Colitis

This article originally appeared here.
Share this content:
Relapse Rate 18.6 Percent for Ulcerative Colitis
Relapse Rate 18.6 Percent for Ulcerative Colitis

WEDNESDAY, March 1, 2017 (HealthDay News) -- For patients with ulcerative colitis (UC) in clinical, endoscopic, and histological remission, the rate of relapse is 18.6 percent over a median follow-up of nine months, according to a study published online Feb. 21 in the Journal of Gastroenterology and Hepatology.

Rajan Dhingra, M.D., from the All India Institute of Medical Sciences in New Delhi, and colleagues examined the relapse rate in patients with UC in clinical, endoscopic, and histological remission. Patients were followed for one year to assess the effect of clinical, dietary, and psychological factors on relapse. Data were included for 97 patients followed for a mean of nine±2.3 months.

The researchers found that 18.6 percent of patients relapsed, with a median time to relapse of 3.5 months. Significantly higher nonsteroidal anti-inflammatory drug (NSAID) use within 15 days of relapse; respiratory infection within four weeks; use of steroids more than once in the past; higher consumption of calcium, riboflavin, and vitamin A; and lower sugar intake were seen for more relapsers in univariate analysis. On multivariate analysis, significant predictors of relapse were NSAID use (hazard ratio, 6.41; 95 percent confidence interval, 1.88 to 21.9) and vitamin A intake (hazard ratio, 1.008; 95 percent confidence interval, 1 to 1.016).

"With a relapse rate of 18.6 percent over a follow-up of nine months in patients with UC in clinical, endoscopic and histological remission, independent predictors of relapse were history of NSAIDs use within 15 days of relapse and higher intake of vitamin A," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Ocrevus to Treat Severe Form of Multiple Sclerosis

FDA Approves Ocrevus to Treat Severe Form of ...

First drug sanctioned in United States for primary progressive multiple sclerosis

Study Explores Links Between Zika, GBS, Microcephaly in Brazil

Study Explores Links Between Zika, GBS, Microcephaly in ...

Apparent resurgence of Zika virus and GBS early in 2016, but no subsequent increase in microcephaly

Inadvertent HPV Vax Doesn't Up Risk of Poor Pregnancy Outcomes

Inadvertent HPV Vax Doesn't Up Risk of Poor ...

No increased risk of major birth defect, spontaneous abortion, preterm birth, low birth weight, SGA

is free, fast, and customized just for you!

Already a member?

Sign In Now »